OKAPI:Orbits | $14,830,855 | (Apr 29, 2025)
Overture Life | $20,600,000 | (Apr 29, 2025)
Symbiotic(US) | $29,000,000 | (Apr 29, 2025)
Ori Biotech
United Kingdom
- London, England
- 18/01/2022
- Series B
- $100,000,000
Ori Biotech is a London- and New Jersey-based leader in CGT manufacturing technology that has developed a proprietary, bespoke and flexible manufacturing platform, which enables patient access to a new generation of personalised, lifesaving treatments.
By fully automating and standardising CGT manufacturing in a closed platform, Ori offers therapeutics developers the opportunity to seamlessly scale from pre-clinical process development to commercial scale manufacturing.
So complex manufacturing challenges can be put where they belong – in the past.
- Industry Automation Machinery Manufacturing
- Website https://oribiotech.com/
- LinkedIn https://www.linkedin.com/company/oribiotech-ltd/about/
Related People
Jason C. FosterFounder
United Kingdom -
London, England
Leveraging my commercial expertise and detailed knowledge of the UK, US and EU healthcare markets, I help build organizations that maximize the value of their products & services to improve health and achieve significant returns for investors.
Lightrun | $70,000,000 | (Apr 29, 2025)
NetFoundry | $12,000,000 | (Apr 29, 2025)
node.energy | $17,088,369 | (Apr 29, 2025)
Cipher Surgical | $10,000,000 | (Apr 29, 2025)
Ovo Labs | $5,372,520 | (Apr 29, 2025)
P-1 AI | $23,000,000 | (Apr 29, 2025)
Deferred | $3,600,000 | (Apr 29, 2025)
Fora Travel | $40,000,000 | (Apr 29, 2025)
Poppins | $5,697,525 | (Apr 29, 2025)